Affecting 20 million people worldwide, schizophrenia remains one of the most common and serious mental illnesses. For the past two decades, over 50 clinical trials have examined the direct impact of modulating components of the endocannabinoid system (ECS) in the contexts of psychosis and schizophrenia.
The CannaKeys schizophrenia treatment algorithm is based on review and analysis of scientific literature and clinical expert opinion. Focused on aspects that can be controlled in the clinical setting, it is designed to be used as a tool for creating optimal cannabinoid-based therapeutics for schizophrenic patients while managing the complexities of the endocannabinoid system.
If you are seeing this message, you are not a CannaKeys subscriber and can't download this cannabis treatment algorithm.
Get our Chronic Pain Treatment Algorithm ebooks for Clinicians and Patients.
Or subscribe to CannaKeys.com to access all of our research dashboards and treatment algorithms.
Evidence-based Guidelines for Cannabis Therapeutics
We offer a systematic approach that physicians and healthcare professionals can use to make evidence-based decisions when prescribing cannabis or cannabinoids to treat schizophrenia. Factors that can make a significant difference in optimizing patient outcomes and producing effective antipsychotic effects include the choice of a primary cannabinoid, specific dosing protocols, and form of administration.
Screening Process
Includes risk assessment, possible contraindications, and potential cannabinoid-to-pharmaceutical drug interactions.
Cannabinoid Treatment Plans
Dosing protocols consider patient preference regarding cognitive changes and altered states, and include starting dose, maximum daily dose, and titration rates for primary cannabinoid.
Cannabis-based Terpenes
Terpenes with therapeutic potential for the mitigating the symptoms of schizophrenia with links to clinical studies.
Nutraceuticals and Supplements
All relevant herbs and nutraceuticals that interact with the endocannabinoid system or the broader endocannabinoidome with clinical evidence for treating schizophrenic symptoms.
Microbiome and Dietary considerations
All dietary considerations and food products that engage the microbiome and interact with the endocannabinoid system or the broader endocannabinoidome with clinical evidence for treating or mitigating schizophrenic symptoms.
